Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model

Journal of Controlled Release

Volumn 150, Issue 1, 2011, Pages 49-55

  Roa, Wilson H ^a   Azarmi, Shirzad ^a,b   Al Hallak, M H D Kamal ^a,c   Finlay, Warren H ^a   Magliocco, Anthony M ^d   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Doxorubicin; Drug delivery; Inhalable nanoparticles; Lung cancer

Indexed keywords

BALB/C MICE; CARDIAC TOXICITY; CARRIER PARTICLES; CONTROL GROUPS; DOXORUBICIN; FREEZE DRYING; IN-CONTROL; INHALABLE NANOPARTICLES; INTRAVENOUS INJECTIONS; KAPLAN-MEIER; LUNG CANCER; MOUSE MODELS; NANOPARTICLE POWDERS; NON-INVASIVE; SALINE SOLUTIONS; TREATMENT GROUP; TUMOR MASS;

BIOLOGICAL ORGANS; DISEASES; DRUG DELIVERY; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; SUGARS; TUMORS;

ANIMALS;

DOXORUBICIN; LACTOSE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; FREEZE DRYING; HISTOPATHOLOGY; LUNG CANCER; LUNG PARENCHYMA; LUNG TUMOR; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POWDER; PRIORITY JOURNAL; SPRAY DRYING;

ADMINISTRATION, INHALATION; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NANOPARTICLES;

EID: 79951942271     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.10.035     Document Type: Article

References (40)

1. A. Jemal, M.J. Thun, L.A. Ries, H.L. Howe, H.K. Weir, M.M. Center, E. Ward, X.C. Wu, C. Eheman, R. Anderson, U.A. Ajani, B. Kohler, B.K. Edwards, Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control, J. Natl Cancer Inst. 100 (2008) 1672-1694.
2. C.L. Tseng, W.Y. Su, K.C. Yen, K.C. Yang, F.H. Lin, The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation, Biomaterials 30 (2009) 3476-3485.
3. H.A. Azim Jr., A.K. Ganti, Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand? Cancer Treat. Rev. 32 (2006) 630-636. (Pubitemid 44645025)
4. V.T. DeVita Jr., E. Chu, A history of cancer chemotherapy, Cancer Res. 68 (2008) 8643-8653.
5. C.J. Hitzman, L.W. Wattenberg, T.S. Wiedmann, Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles, J. Pharm. Sci. 95 (2006) 1196-1211.
6. S. Azarmi, W.H. Roa, R. Lobenberg, Targeted delivery of nanoparticles for the treatment of lung diseases, Adv. Drug Deliv. Rev. 60 (2008) 863-875.
7. G.A. Otterson, M.A. Villalona-Calero, W. Hicks, X. Pan, J.A. Ellerton, S.N. Gettinger, J. R. Murren, Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer, Clin. Cancer Res. 16 (2010) 2466-2473.
8. E.M. Gipps, P. Groscurth, J. Kreuter, P.P. Speiser, Distribution of polyhexylcyanoacrylate nanoparticles in nude mice over extended times and after repeated injection, J. Pharm. Sci. 77 (1988) 208-209.
9. S.M. Moghimi, A.C. Hunter, J.C. Murray, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev. 53 (2001) 283-318.
10. M.E. Davis, Z.G. Chen, D.M. Shin, Nanoparticle therapeutics: an emerging treatment modality for cancer, Nat. Rev. Drug Discov. 7 (2008) 771-782.
11. L. Araujo, R. Lobenberg, J. Kreuter, Influence of the surfactant concentration on the body distribution of nanoparticles, J. Drug Target. 6 (1999) 373-385. (Pubitemid 29237593)
12. J.O. Sham, Y. Zhang, W.H. Finlay, W.H. Roa, R. Lobenberg, Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung, Int. J. Pharm. 269 (2004) 457-467.
13. L. Ely, W. Roa, W.H. Finlay, R. Lobenberg, Effervescent dry powder for respiratory drug delivery, Eur. J. Pharm. Biopharm. 65 (2007) 346-353.
14. S. Azarmi, R. Lobenberg, W.H. Roa, S. Tai, W.H. Finlay, Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles, Drug Dev. Ind. Pharm. 34 (2008) 943-947.
15. N. Tsapis, D. Bennett, B. Jackson, D.A. Weitz, D.A. Edwards, Trojan particles: large porous carriers of nanoparticles for drug delivery, Proc. Natl Acad. Sci. USA 99 (2002) 12001-12005.
16. M. Joshi, A. Misra, Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization, Int. J. Pharm. 223 (2001) 15-27.
17. M. Joshi, A.N. Misra, Pulmonary disposition of budesonide from liposomal dry powder inhaler, Methods Find. Exp. Clin. Pharmacol. 23 (2001) 531-536. (Pubitemid 34229356)
18. J. Liu, T. Gong, H. Fu, C. Wang, X. Wang, Q. Chen, Q. Zhang, Q. He, Z. Zhang, Solid lipid nanoparticles for pulmonary delivery of insulin, Int. J. Pharm. 356 (2008) 333-344.
19. K. Ohashi, T. Kabasawa, T. Ozeki, H. Okada, One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis, J. Control. Release 135 (2009) 19-24.
20. T.R. Desai, J.P. Wong, R.E. Hancock, W.H. Finlay, A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling, J. Pharm. Sci. 91 (2002) 482-491.
21. S. Azarmi, X. Tao, H. Chen, Z. Wang, W.H. Finlay, R. Lobenberg, W.H. Roa, Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles, Int. J. Pharm. 319 (2006) 155-161.
22. K.M. Al-Hallak, S. Azarmi, A. Anwar-Mohamed, W.H. Roa, R. Lobenberg, Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy? Eur. J. Pharm. Biopharm. 76 (2010) 112-119.
23. L.G. Sweeney, Z. Wang, R. Loebenberg, J.P. Wong, C.F. Lange, W.H. Finlay, Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery, Int. J. Pharm. 305 (2005) 180-185.
24. A.E. Gulyaev, S.E. Gelperina, I.N. Skidan, A.S. Antropov, G.Y. Kivman, J. Kreuter, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm. Res. 16 (1999) 1564-1569.
25. P. Couvreur, B. Kante, V. Lenaerts, V. Scailteur, M. Roland, P. Speiser, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J. Pharm. Sci. 69 (1980) 199-202.
26. S.E. Gelperina, A.S. Khalansky, I.N. Skidan, Z.S. Smirnova, A.I. Bobruskin, S.E. Severin, B. Turowski, F.E. Zanella, J. Kreuter, Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma, Toxicol. Lett. 126 (2002) 131-141.
27. W.H. Finlay, The Mechanics of Inhaled Pharmaceutical Aerosols: an Introduction, Academic Press, San Diego, 2001.
28. Y. Naomoto, H. Kondo, N. Tanaka, K. Orita, Novel experimental models of human cancer metastasis in nude mice: lung metastasis, intraabdominal carcinomatosis with ascites, and liver metastasis, J. Cancer Res. Clin. Oncol. 113 (1987) 544-549.
29. Y. Matsumura, K. Kataoka, Preclinical and clinical studies of anticancer agent-incorporating polymer micelles, Cancer Sci. 100 (2009) 572-579.
30. S.W. Choi, J.H. Kim, Design of surface-modified poly(D, L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone, J. Control. Release 122 (2007) 24-30.
31. J. Sakamoto, A. Annapragada, P. Decuzzi, M. Ferrari, Antibiological barrier nanovector technology for cancer applications, Expert Opin. Drug Deliv. 4 (2007) 359-369.
32. S. Gill, R. Lobenberg, T. Ku, S. Azarmi, W. Roa, E.J. Prenner, Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review, J. Biomed. Nanotechnol. 3 (2007) 107-119. (Pubitemid 351877160)
33. D.A. Edwards, A. Ben-Jebria, R. Langer, Recent advances in pulmonary drug delivery using large, porous inhaled particles, J. Appl. Physiol. 85 (1998) 379-385. (Pubitemid 28365799)
34. G. Oberdorster, E. Oberdorster, J. Oberdorster, Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles, Environ. Health Perspect. 113 (2005) 823-839.
35. C. Muhlfeld, B. Rothen-Rutishauser, F. Blank, D. Vanhecke, M. Ochs, P. Gehr, Interactions of nanoparticles with pulmonary structures and cellular responses, Am. J. Physiol. Lung Cell. Mol. Physiol. 294 (2008) L817-L829.
36. M.H. Al-Hallak, S. Azarmi, C. Sun, P. Lai, E.J. Prenner, W.H. Roa, R. Lobenberg, Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation, AAPS J. 12 (2010) 294-299.
37. C. Goncalves, E. Torrado, T. Martins, P. Pereira, J. Pedrosa, M. Gama, Dextrin nanoparticles: studies on the interaction with murine macrophages and blood clearance, Colloids Surf., B Biointerfaces 75 (2010) 483-489.
38. C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles, Biomaterials 31 (2010) 3657-3666.
39. M.J. Clift, B. Rothen-Rutishauser, D.M. Brown, R. Duffin, K. Donaldson, L. Proudfoot, K. Guy, V. Stone, The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line, Toxicol. Appl. Pharmacol. 232 (2008) 418-427.
40. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer, Biodegradable long-circulating polymeric nanospheres, Science 263 (1994) 1600-1603. (Pubitemid 24128361)